医薬品リファレンス
Blinatumomab
Blinatumomab is a medicine in the class oncology. It is used for acute lymphocytic leukemia.
- 薬効分類: Oncology
- 効能・効果: acute lymphocytic leukemia
最終更新日 出典: US FDA label
医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。
このページの臨床コンテンツは英語でのみ提供されています。
要点
- 薬効分類
- Oncology
- ATCコード
- L01FX07
- 一般的な規格
- 35 mcg
- 既知の相互作用
- 14 (中等度: 13 · 軽度: 1)
- 商品名
- 2
- 国・市場
- 2
何に使われるか
作用のしくみ
Bispecific CD19-directed CD3 T-cell engager that connects CD3 on T-cells with CD19 on benign and malignant B-cells, activating T-cells and causing redirected lysis of CD19+ cells.
成人の通常用量(添付文書の要約)
MRD-positive B-cell precursor ALL: patients 45 kg or more 28 mcg/day by continuous IV infusion on Days 1-28 of each 42-day cycle (14-day treatment-free interval); 1 induction cycle then up to 3 consolidation cycles
妊娠と授乳
- 妊娠
- Unsafe May cause fetal harm based on mechanism; no human data. Can cause B-cell lymphocytopenia in exposed infants. Verify pregnancy status before treatment.
- 授乳
- Unsafe Advise not to breastfeed during treatment and for 48 hours after the last dose.
報告されている副作用
- Pyrexia
- Infusion-related reactions
- Headache
- Infection
- Musculoskeletal pain
- Neutropenia
警告(枠囲み警告)
- Cytokine release syndrome, which may be life-threatening or fatal, occurred. Interrupt or discontinue and treat with corticosteroids as recommended.
禁忌
- Known hypersensitivity to blinatumomab or any component of the formulation.
注意が必要な方
- CRS: monitor; interrupt for severe CRS and discontinue permanently for life-threatening CRS.
- Neurological toxicities including ICANS; consider seizure prophylaxis in Down syndrome patients.
- Serious infections occurred in approximately 25% of patients; consider prophylactic antibiotics and monitor.
妊娠中または授乳中であること、腎臓や肝臓の病気、アレルギー、ほかに使用しているすべての薬やサプリメントについて、薬剤師または医師にお伝えください。
主な相互作用 (14)
- Blinatumomab + Carbamazepine Moderate
- Blinatumomab + Cyclosporin Moderate
- Blinatumomab + Ethosuximide Moderate
- Blinatumomab + Phenytoin Moderate
- Blinatumomab + Quinidine Moderate
- Blinatumomab + Quinine Moderate
- Blinatumomab + Siponimod Moderate
- Blinatumomab + Sirolimus Moderate
- Blinatumomab + Tacrolimus Moderate
- Blinatumomab + Theophylline Moderate
Pro+会員向け
ページ全体を見る
アカウントを作成してPro+トライアルを始めると、Blinatumomabの完全なモノグラフ(用量、妊娠・授乳、副作用、警告、すべての相互作用)を表示できます。
- Dosing by age, kidney and liver function, and further dose lines
- Renal and hepatic dose adjustments
- Paediatric dosing
- How to give it
- Pharmacokinetics
- Patient counselling points
WebでPro+を14日間無料でお試し。カード登録不要。
同じ分類のほかの薬剤
よくある質問
What is Blinatumomab used for?
Blinatumomab is a medicine in the class oncology. It is used for Acute lymphocytic leukemia.
What side effects have been reported with Blinatumomab?
Pyrexia, Infusion-related reactions, Headache, Infection, Musculoskeletal pain, Neutropenia. Serious warning: Cytokine release syndrome, which may be life-threatening or fatal, occurred.
Can Blinatumomab be taken in pregnancy or while breastfeeding?
Pregnancy: Unsafe. May cause fetal harm based on mechanism; no human data. Can cause B-cell lymphocytopenia in exposed infants. Verify pregnancy status before treatment. Breastfeeding: Unsafe. Advise not to breastfeed during treatment and for 48 hours after the last dose.
What does Blinatumomab interact with?
MediHelp lists 14 known interactions for Blinatumomab. Moderate: 13 · Minor: 1. The most serious include Carbamazepine, Cyclosporin, Ethosuximide.
完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで
MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。